Conventional and novel [ 18 F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma.

Autor: Leithner D; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.; Department of Radiology, NYU Grossman School of Medicine, New York, USA., Flynn JR; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Devlin SM; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mauguen A; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fei T; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zeng S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Zheng J; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Imber BS; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hubbeling H; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Mayerhoefer ME; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.; Department of Radiology, NYU Grossman School of Medicine, New York, USA.; Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria., Bedmutha A; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA., Luttwak E; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Corona M; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Hematology and Hemotherapy Service, Hospital Universitario 12 de Octubre, Madrid, Spain., Dahi PB; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Luna de Abia A; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Bone Marrow Transplantation Unit, Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain., Landego I; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA., Lin RJ; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Palomba ML; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Scordo M; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Park JH; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tomas AA; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Department of Hematology, Hospital Universitario Puerta de Hierro, Madrid, Spain., Salles G; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Lafontaine D; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA., Michaud L; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.; Department of Nuclear Medicine and Molecular ImagingLausanne University Hospital (CHUV), Lausanne, Switzerland., Shah GL; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Perales MA; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA., Shouval R; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, 530 E74th Street, NY, 10021, New York, USA. shouvalr@mskcc.org.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. shouvalr@mskcc.org., Schöder H; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA.
Jazyk: angličtina
Zdroj: Journal of hematology & oncology [J Hematol Oncol] 2024 Apr 23; Vol. 17 (1), pp. 21. Date of Electronic Publication: 2024 Apr 23.
DOI: 10.1186/s13045-024-01540-x
Abstrakt: Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from pre-CAR-T 18 F-fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) scans (n = 341) of 180 patients (121 male; median age, 66 years). Three conventional (maximum standardized uptake value [SUVmax], metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and 116 novel radiomic features were assessed, along with inflammatory markers, toxicities, and outcomes. At both pre-apheresis and pre-infusion time points, conventional PET features of disease correlated with elevated inflammatory markers. At pre-infusion, MTV was associated with grade ≥ 2 cytokine release syndrome (odds ratio [OR] for 100 mL increase: 1.08 [95% confidence interval (CI), 1.01-1.20], P = 0.031), and SUVmax was associated with failure to achieve complete response (CR) (OR 1.72 [95% CI, 1.24-2.43], P < 0.001). Higher pre-apheresis and pre-infusion MTV values were associated with shorter progression-free survival (PFS) (HR for 10-unit increase: 1.11 [95% CI, 1.05-1.17], P < 0.001; 1.04 [95% CI, 1.02-1.07], P < 0.001) and shorter overall survival (HR for 100-unit increase: 1.14 [95% CI, 1.07-1.21], P < 0.001; 1.04 [95% CI, 1.02-1.06], P < 0.001). A combined MTV and LDH measure stratified patients into high and low PFS risk groups. Multiple pre-infusion novel radiomic features were associated with CR. These quantitative conventional [ 18 F]FDG PET/CT features obtained before CAR-T cell infusion, which were correlated with inflammation markers, may provide prognostic biomarkers for CAR-T therapy efficacy and toxicity. The use of conventional and novel radiomic features may thus help identify high-risk patients for earlier interventions.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: